Business Context and Reporting Period
This Form 6-K filing by ZK International Group Co., Ltd. covers the month ended October 2025. The report details significant changes to the Company's Board of Directors and executive management effective October 3, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- CEO Resignation: Mr. Jiancong Huang resigned as Chief Executive Officer effective October 3, 2025. He will continue to serve as Chairman of the Board.
- Director Resignations: Mr. Guolin Wang and Mr. Lie Cao resigned as directors effective October 3, 2025, to pursue other business commitments. The resignations were not due to disagreements with the Company.
- New Appointments: Mr. Ruihong Ma was appointed as the new Chief Executive Officer and Director. Ms. Yannan Chuai was appointed as a Director and designated as an "independent" director.
- Committee Roles: Ms. Chuai was appointed Chair of the Nominating Committee and a member of the Audit and Compensation Committees.
Management Commentary and Compensation
The Board approved employment agreements for the new leadership:
- Mr. Ruihong Ma: Appointed CEO and Director with an annual compensation of US$5,000. He brings over 15 years of experience in engineering, pharmaceutical, and medical equipment sectors.
- Ms. Yannan Chuai: Appointed Independent Director with an annual compensation of US$5,000. She has extensive experience in human resources management and corporate administration.
The filing states there are no family relationships between the new appointees and other employees or board members.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) and Director Offer Letter (Exhibit 10.2) for additional terms not summarized in the filing.
- Confirm the transition plan for the CEO role given the immediate resignation of Mr. Huang and appointment of Mr. Ma.
- Review the Company's subsequent filings for any financial impact or strategic shifts resulting from the leadership changes.
- Validate the independence status of Ms. Chuai against Nasdaq Marketplace Rules as claimed by the Board.